{
    "clinical_study": {
        "@rank": "28451", 
        "arm_group": [
            {
                "arm_group_label": "Ticagrelor", 
                "arm_group_type": "Experimental", 
                "description": "Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting 12\u00b16 hours post LD, until discharge."
            }, 
            {
                "arm_group_label": "Clopidogrel", 
                "arm_group_type": "Active Comparator", 
                "description": "Clopidogrel 600mg loading dose (LD), followed by a 150mg once daily maintenance dose (MD) starting 12\u00b16 hours post LD, until discharge."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a two-center, prospective, randomized, single-blind, investigator initiated,\n      pharmacodynamic study of parallel design, carried out in 2 PCI-capable cardiology centers\n      (Patras University Hospital and Konstantopoulio General Hospital of Athens).\n\n      Patients with ST elevation myocardial infarction, having undergone fibrinolysis in the\n      previous 3 to 48 hours, who present high residual PR (defined as PRU \u2265208 ) on admission,\n      pre coronary angiography, will be randomized after written informed consent, in a 1:1 ratio\n      to either:\n\n      Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting\n      12\u00b16 hours post LD, until discharge.\n\n      Or\n\n      Clopidogrel 600mg loading dose (LD), followed by a 150mg once daily maintenance dose (MD)\n      starting 12\u00b16 hours post LD, until discharge.\n\n      Platelet reactivity assessment will be performed at randomization (Hour 0) and at 2, 24\n      hours after randomization, as well as pre-discharge, using the VerifyNow assay, in platelet\n      reactivity units (PRU).\n\n      Documentation of major adverse cardiac events (death, myocardial infarction, stroke,\n      ischemia driven revascularization procedure with PCI or CABG) and bleeding (according to\n      BARC criteria) will be performed until patient's discharge."
        }, 
        "brief_title": "Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "ST Elevation Myocardial Infarction", 
            "Fibrinolysis", 
            "P2Y12 Inhibitor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 18-85 years old\n\n          2. Patients with STEMI, having undergone fibrinolytic therapy in the previous 3 to 48\n             hours\n\n          3. Presenting HPR (\u2265208 PRU) post 300mg clopidogrel loading dose ( assessment\n             immediately before coronary angiography)\n\n          4. Informed consent obtained in writing\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Breastfeeding\n\n          -  Inability to give informed consent\n\n          -  Cardiogenic shock\n\n          -  Major periprocedural complications (death, stent thrombosis, vessel perforation,\n             arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous\n             antiarrhythmic agents, respiratory failure requiring intubation, vascular injury\n             (arteriovenous shunt, retroperitoneal bleeding), major bleeding (need for bood\n             transfusion or drop in haemoglobin post-PCI by \u2265 5 gr/ dl or intracranial bleeding)\n\n          -  Known hypersensitivity to ticagrelor or clopidogrel\n\n          -  History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal\n             bleeding within the previous 3 months.\n\n          -  Other bleeding diathesis, or considered by investigator to be at high risk for\n             bleeding\n\n          -  Any previous history of stroke, intracranial hemorrhage or disease (neoplasm,\n             arteriovenous malformation, aneurysm).\n\n          -  Thombocytopenia (<100.000 / \u03bcL) at randomization\n\n          -  Anaemia (Hct <30%) at randomization\n\n          -  Polycytaemia (Hct > 52%) at randomization\n\n          -  Periprocedural IIb/IIIa inhibitors administration\n\n          -  Per os anticoagulants\n\n          -  Recent (< 6 weeks) major surgery or trauma, including GABG.\n\n          -  Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs)\n             or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration\n             of the study.\n\n          -  Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole,\n             itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir,\n             saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A\n             substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A\n             inducers (rifampin /rifampicin, phenytoin, carbamazepine).\n\n          -  Increased risk of bradycardiac events.\n\n          -  Dialysis required.\n\n          -  Severe uncontrolled chronic obstructive pulmonary disease\n\n          -  Known severe hepatic impairement"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950416", 
            "org_study_id": "PATRASCARDIOLOGY-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ticagrelor", 
                "intervention_name": "Ticagrelor 180mg loading dose and 90mg bid maintenance dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Clopidogrel", 
                "intervention_name": "Clopidogrel 600mg loading dose and 150mg maintenance dose", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clopidogrel", 
                "Ticlopidine", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ST elevation myocardial infarction", 
            "Fibrinolysis", 
            "Ticagrelor", 
            "Clopidogrel", 
            "Platelet reactivity"
        ], 
        "lastchanged_date": "September 21, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Sotirios Patsilinakos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "state": "Attiki", 
                        "zip": "14233"
                    }, 
                    "name": "Konstantopoulio General Hospital of Athens"
                }, 
                "investigator": {
                    "last_name": "Sotirios Patsilinakos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dalex@med.upatras.gr", 
                    "last_name": "Dimitrios Alexopoulos, Professor", 
                    "phone": "00302610999281"
                }, 
                "facility": {
                    "address": {
                        "city": "Patras", 
                        "country": "Greece", 
                        "zip": "26500"
                    }, 
                    "name": "Patras University Hospital"
                }, 
                "investigator": {
                    "last_name": "Dimitrios Alexopoulos, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacodynamic Assessment of Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Exhibiting High Platelet Reactivity Post Fibrinolysis", 
        "overall_contact": {
            "email": "dalex@med.upatras.gr", 
            "last_name": "Dimitrios Alexopoulos, Professor", 
            "phone": "00302610999281"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Greece: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Platelet reactivity at 2 hours post randomization between the 2 treatment arms", 
            "measure": "Platelet reactivity at 2 hours post randomization between the 2 treatment arms", 
            "safety_issue": "No", 
            "time_frame": "2 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950416"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Patras", 
            "investigator_full_name": "Dimitrios Alexopoulos", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Platelet reactivity at 24 hours post randomization between the 2 treatment arms.", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Platelet reactivity pre-discharge between the 2 treatment arms", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }, 
            {
                "measure": "High on treatment platelet reactivity (HPR) rate (\u2265208 PRU) at 2 hours post randomization", 
                "safety_issue": "No", 
                "time_frame": "2 hours"
            }, 
            {
                "measure": "High on treatment platelet reactivity (HPR) rate (\u2265208 PRU) at 24 hours post randomization", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "High on treatment platelet reactivity (HPR) rates (\u2265208 PRU) pre discharge", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }
        ], 
        "source": "University of Patras", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Patras", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}